Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Terns Pharmaceuticals Inc (TERN)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/29/2025: TERN (5-star) is a STRONG-BUY. BUY since 144 days. Simulated Profits (1082.34%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $53.56
1 Year Target Price $53.56
| 5 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 544.4% | Avg. Invested days 40 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/29/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.52B USD | Price to earnings Ratio - | 1Y Target Price 53.56 |
Price to earnings Ratio - | 1Y Target Price 53.56 | ||
Volume (30-day avg) 9 | Beta -0.24 | 52 Weeks Range 1.86 - 48.26 | Updated Date 12/29/2025 |
52 Weeks Range 1.86 - 48.26 | Updated Date 12/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.94% | Return on Equity (TTM) -29.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4221411507 | Price to Sales(TTM) 302.64 |
Enterprise Value 4221411507 | Price to Sales(TTM) 302.64 | ||
Enterprise Value to Revenue 337.47 | Enterprise Value to EBITDA -5.8 | Shares Outstanding 108767281 | Shares Floating 66516712 |
Shares Outstanding 108767281 | Shares Floating 66516712 | ||
Percent Insiders 0.24 | Percent Institutions 83.55 |
Upturn AI SWOT
Terns Pharmaceuticals Inc
Company Overview
History and Background
Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for obesity and metabolic diseases. Founded in 2017, it has advanced its pipeline through strategic development and partnerships, aiming to address significant unmet medical needs in these areas.
Core Business Areas
- Metabolic Diseases: Development of small molecule drugs targeting pathways involved in metabolic diseases like obesity and non-alcoholic steatohepatitis (NASH).
- Obesity: Focus on creating innovative treatments for weight management with potential for long-term efficacy and safety.
Leadership and Structure
Terns Pharmaceuticals Inc. is led by a management team with experience in drug development and the pharmaceutical industry. The company operates with a lean structure focused on research and clinical development, often leveraging external partnerships for manufacturing and commercialization.
Top Products and Market Share
Key Offerings
- TERN-101: A THR-beta agonist designed to treat NASH. TERN-101 is in clinical development, and its market share is yet to be established as it is still in trials. Key competitors in the NASH space include companies developing similar agonists and other therapeutic approaches to NASH.
- TERN-102: An FXR agonist intended for NASH treatment. Similar to TERN-101, TERN-102 is in clinical development with no established market share. It faces competition from other FXR agonists and diverse NASH therapies.
- TERN-201: A small molecule inhibitor of ACC (acetyl-CoA carboxylase) for obesity and NASH. This product is also in the clinical development phase, with its market share to be determined. It competes with other anti-obesity and NASH drugs.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the areas of obesity and metabolic diseases, is characterized by rapid innovation, significant investment in R&D, and a high degree of competition. There is a growing demand for effective treatments due to increasing global prevalence of these conditions.
Positioning
Terns Pharmaceuticals Inc. positions itself as a developer of novel, first-in-class or best-in-class therapies. Its competitive advantage lies in its scientific approach to targeting complex disease pathways and its pipeline of drug candidates in various stages of clinical development.
Total Addressable Market (TAM)
The global market for obesity and NASH treatments is substantial and projected to grow significantly. Estimates for the NASH market alone range in the tens of billions of dollars annually, while the obesity market is even larger. Terns Pharmaceuticals Inc. aims to capture a significant share of this TAM with its innovative therapeutic candidates.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline targeting key metabolic pathways.
- Experienced management team with biopharmaceutical development expertise.
- Focus on high-need therapeutic areas with significant market potential.
Weaknesses
- Clinical-stage company, meaning products are not yet commercialized.
- Reliance on successful clinical trial outcomes.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Growing global prevalence of obesity and metabolic diseases.
- Advancements in scientific understanding of these diseases.
- Potential for strategic partnerships and collaborations.
Threats
- High failure rate in clinical drug development.
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Regulatory hurdles and long approval processes.
- Pricing pressures and reimbursement challenges.
Competitors and Market Share
Key Competitors
- Madrigal Pharmaceuticals (MDGL)
- 89bio, Inc. (ETNB)
- Pfizer Inc. (PFE)
- Novo Nordisk (NVO)
Competitive Landscape
Terns Pharmaceuticals Inc. competes in highly dynamic and competitive markets. Its advantages lie in its novel drug targets and potentially differentiated mechanisms of action. Disadvantages include its early-stage status and the financial resources of larger, established competitors.
Growth Trajectory and Initiatives
Historical Growth: Growth has been characterized by the progression of its pipeline candidates through preclinical and clinical stages, securing financing, and building its research capabilities.
Future Projections: Future growth is projected to be driven by successful clinical trial results, regulatory approvals, and eventual commercialization of its lead drug candidates. Analyst projections will focus on the potential peak sales of these therapies.
Recent Initiatives: Recent initiatives likely include advancing clinical trials for TERN-101, TERN-102, and TERN-201, as well as potential collaborations or licensing agreements to fund further development and expand its therapeutic reach.
Summary
Terns Pharmaceuticals Inc. is a promising clinical-stage biopharmaceutical company with a focused pipeline in obesity and metabolic diseases. Its innovative approach and experienced team are strengths, but it faces the inherent risks of drug development and intense competition. Successful clinical trials and strategic partnerships will be crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Financial News Outlets
- Industry Analyst Reports
- Pharmaceutical Databases
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. All data is subject to change and should be independently verified. Investing in clinical-stage biopharmaceutical companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Terns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO & Director Ms. Amy L. Burroughs M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.ternspharma.com |
Full time employees 59 | Website https://www.ternspharma.com | ||
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.